Skip to content

Clinical research on Qijiaoshengbai Capsules in prophylaxis and treatment of leucopenia (deficiency of qi and blood syndrome) induced by chemotherapy with lung cancer or breast cancer patients

Clinical research on Qijiaoshengbai Capsules in prophylaxis and treatment of leucopenia (deficiency of qi and blood syndrome) induced by chemotherapy with lung cancer or breast cancer patients

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-IPR-15006759
Enrollment
Unknown
Registered
2015-07-16
Start date
2015-07-30
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

leucopenia (deficiency of qi and blood syndrome)

Interventions

Sponsors

Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Diagnosed as lung cancer or breast cancer by imaging and/or histopathology or cytology; 2. Age between 18~75 years old, not limited to gender; 3. Performance status(KPS) score above 60 points; 4. The excepted survival time >=3 months; 5. The lung cancer patients who can complete 1 cycle of chemotherapy with platinum-based two medicine (cisplatin or carboplatin); The breast cancer patients who can complete 1 cycle of chemotherapy with paclitaxel-based two medicine (Taxol or docetaxel); 6. WBC>=3.5*10^9/L before chemotherapy; 7. In accordance with the standards of deficiency of qi and blood syndrome; 8. No serious diseases of heart, liver, kidney, blood and other systems; 9. Volunteers, and signed the informed consent.

Exclusion criteria

Exclusion criteria: 1. Not comply with the above inclusion criteria; 2. Bone marrow metastasis; 3. Pregnant or lactating women; 4. Mental patients; 5. Unable to follow the prescription in previous treatment.

Design outcomes

Primary

MeasureTime frame
WBC;NEUT;

Secondary

MeasureTime frame
TCM syndrome;

Countries

China

Contacts

Public ContactLi Hou
houli1203@126.com+86 13488695608

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026